SBIR/STTR Research Award

HIGH-LEVEL EXPRESSION OF HIV GP120 IN MAMMALIAN CELLS

Award identifier 7937f33e83142df48cfebc37602225037789f2d40201639d30b033ef70079fe1Awarding agency Department of Health and Human Services

Award amount

$500,000

Program and phase

SBIR · Phase II

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
PROGENICS PHARMACEUTICALS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
YLYKVRPCTCR3
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE HUMAN CELL SURFACE GLYCOPROTEIN CD4 IS THE CELLULAR RECEPTOR FOR THE HIV AND BINDS WITH HIGH AFFINITY TO THE HIV EXTERIOR ENVELOPE GLYCOPROTEIN, GPL20. AT PRESENT, A DETAILED MOLECULAR PICTURE OF THIS INTERACTION IS UNAVAILABLE BECAUSE OF THE OVERALL COMPLEXITY OF THESE MOLECULES AND THE DIFFICULTY IN OBTAINING LARGE QUANTITIES OF PURIFIED, NATIVE, RECOMBINANT HIV GPL20 DUE TO INHERENT DIFFICULTIES IN ACHIEVING HIGH-LEVEL EXPRESSION IN MAMMALIAN CELLS. THE GOAL OF THIS PROJECT IS TO GENERATE EUKARYOTIC EXPRESSION VECTORS ENCODING HIV-L GPL20 THAT WILL DIRECT THE HIGH-LEVEL EXPRESSION IN MAMMALIAN CELLS OF GPL20 IN A SYSTEM AMENABLE TO LARGE-SCALE PRODUCTION. THE MAJOR ADVANTAGE OF THIS SYSTEM OVER ALREADY EXISTING SYSTEMS IS THAT EXPRESSION WILL BE STABLE, VIRUS-FREE, AND WILL ENCODE NATIVE, CORRECTLY GLYCOSYLATED HIV-L GPL20. THE GOAL OF DEVELOPING THIS EXPRESSION SYSTEM IS TO PRODUCE LARGE QUANTITIES OF MATERIAL FOR DETAILED BIOCHEMICAL, BIOPHYSICAL, CRYSTALLOGRAPHIC, AND IMMUNOLOGIC INVESTIGATIONS. THESE STUDIES WILL NOT ONLY PROVIDE A PRECISE MOLECULAR DESCRIPTION OF THE BINDING OF HIV GPL20 TO CD4, BUT WILL ALSO PROVIDE NEW INSIGHT INTO THE INTERACTIONS BETWEEN HIV AND THE HOST IMMUNE SYSTEM. A DETAILED UNDERSTANDING OF THESE EVENTS WILL PERMIT THE DESIGN BOTH OF NOVEL THERAPEUTIC AGENTS WHICH INHIBIT THIS STEP IN THE VIRAL REPLICATIVE-CYCLE AND OF RECOMBINANT VACCINES.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

39 SBIR/STTR records share this UEI (1990–2007). Reported award amounts total $29,853,777. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.